在携带HepG2的小鼠中,Jaspine B的脂调节和抗瘤活性
Jihoon Lee1,2, Ji-Hyeon Jeon1, Minyeong Pang3
1College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, 80 Daehakro, Dae-gu, 41566, Republic of Korea.
Archives of pharmacal research
|July 18, 2025
概括
雅思B通过抑制斯芬戈素激酶1 (SphK1) 和降低斯芬戈-1-酸盐 (S1P) 水平,对肝细胞癌产生抗癌作用. 它在细胞培养和小鼠模型中都表现出有效性,表明其作为治疗剂的潜力.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 肝细胞癌 (HCC) 仍然是一个重大的全球健康挑战.
- 向螺旋脂代谢,特别是螺旋氨酸激酶1 (SphK1) 和其产物螺旋氨酸-1-酸盐 (S1P),是一种潜在的抗癌策略.
- 莉花B是一种具有潜在抗癌特性的化合物,需要进行研究.
研究的目的:
- 评估Jaspine B对肝细胞癌 (HepG2细胞) 的抗癌疗效.
- 阐明贾斯B的抗癌活性的潜在机制,重点关注SphK1和S1P.
- 在小鼠模型中评估Jaspine B的体内疗效和药理动力学特性.
主要方法:
- 进行了细胞毒性测试,以确定Jaspine B.的半最大抑制度 (IC50).
- 分析了用 Jaspine B. 治疗的 HepG2 细胞中的 sfingosine kinase 1 (SphK1) 表达和 sfingosine-1-phosphate (S1P) 水平.
- 使用流式细胞计量评估了亡.
- 在体内研究中,采用异种移植的小鼠接受了Jaspine B治疗,并对瘤大小,体重和器官重量进行了监测.
- 在接受治疗的小鼠中测量了瘤组织中的SphK1表达和血S1P水平.
- 评估了Jaspine B的药理动力学特性和瘤分布.
主要成果:
- 贾斯B对HepG2细胞具有显著的细胞毒性,IC50为2.6μM.
- 贾斯B以剂量依赖的方式降低了SphK1表达和S1P水平,并在HepG2细胞中诱导了亡.
- 在体内,贾斯B治疗减少了HepG2-异种移植小鼠的瘤大小,而不会导致身体或器官体重的显著变化.
- 斯B在瘤组织中达到有效度,超过其细胞毒性和SphK1抑制的IC50.
- 抗癌作用和血S1P水平的降低与选择性SphK1抑制剂PF543相当.
结论:
- 斯B是一种强大的SphK1抑制剂,并且在体外和体内表现出显著的抗癌活性,对肝细胞癌具有显著的抗癌活性.
- 贾斯B具有有利的药理动力学和瘤分布特性,使其成为HCC治疗的有希望的候选人.
- 血S1P水平降低可能作为HCC治疗中对SphK1抑制剂的治疗反应的预测生物标志物.
相关概念视频
01:20The JAK-STAT Signaling Pathway
9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.3K
01:22PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K